专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012044462A1 ECHO CONTROL OPTIMIZATION 审中-公开
标题翻译： ECHO控制优化
公开(公告)号：WO2012044462A1
公开(公告)日：2012-04-05
申请号：PCT/US2011/051692
申请日：2011-09-15
申请人： CISO TECHNOLOGY, INC. , RAMALINGAM, Thiyagesan , PANDYA, Bhargav, G. , SKRABUTENAS, Gary, A.
发明人： RAMALINGAM, Thiyagesan , PANDYA, Bhargav, G. , SKRABUTENAS, Gary, A.
IPC分类号： H04M9/08 , H04B3/23
CPC分类号： H04B3/23
摘要： In one implementation, a conference hosted on a conference bridge that includes an echo control device that classifies the echo return loss of a plurality of endpoints. The endpoints may include endpoints on internet protocol (IP) networks and public switched telephone networks (PSTN). The echo control of the endpoints is controlled independently. An echo classification module calculates the echo return loss value of the associated echo tail of the endpoint and chooses an appropriate echo control mode. If the echo return loss is above a high threshold, a pass through mode is activated. If the echo return loss is below a low threshold, a full echo cancellation mode is activated. If the echo return loss is between the low threshold and the high threshold, an echo suppression mode is activated.
摘要翻译：在一个实现中，在会议桥上承载的会议，其包括对多个端点的回波返回损失进行分类的回波控制设备。端点可以包括互联网协议（IP）网络和公共交换电话网络（PSTN）上的端点。端点的回波控制是独立控制的。回波分类模块计算端点的相关回波尾的回波回波损耗值，并选择适当的回波控制模式。如果回波回波损耗高于高阈值，则激活通过模式。如果回波回波损耗低于低阈值，则全反射消除模式被激活。如果回波回波损耗在低阈值和高阈值之间，则回波抑制模式被激活。

2. 发明申请

WO2006040643A2 POLYMORPHIC FORMS OF EFAVIRENZ AND PROCESSES FOR THEIR PREPARATION 审中-公开
标题翻译： EFAVIRENZ的多形态及其制备方法
公开(公告)号：WO2006040643A2
公开(公告)日：2006-04-20
申请号：PCT/IB2005003013
申请日：2005-10-10
申请人： RANBAXY LAB LTD , SHARMA RAMNIK , BHUSHAN KUMAR HARI , ARYAN RAM CHANDER , SINGH NITU , PANDYA BHARGAV , KUMAR YATENDRA
发明人： SHARMA RAMNIK , BHUSHAN KUMAR HARI , ARYAN RAM CHANDER , SINGH NITU , PANDYA BHARGAV , KUMAR YATENDRA
IPC分类号： C07D265/18 , A61K31/535 , A61P31/18
CPC分类号： C07D265/18
摘要： The present invention relates to novel polymorphic forms of efavirenz. The novel polymorphic forms are designated as Forms a, ß, ?, ?1, ?2, ?,d, N, O and P of efavirenz. The present invention further relates to amorphous form of efavirenz. The invention also relates to the processes for their preparation and use in pharmaceutical compositions useful in the treatmentof HIV-1 infection.
摘要翻译：本发明涉及依法韦仑的新型多晶型物。新型多晶型被指定为依法韦仑的形式a，β，α，α1，α2，α，d，N，O和P。本发明还涉及依法韦仑的无定形形式。本发明还涉及其制备和用于治疗HIV-1感染的药物组合物中的方法。

3. 发明申请

WO2006035293A1 POLYMORPHIC FORMS OF QUETIAPINE HEMIFUMARATE 审中-公开
标题翻译：高效液相色谱的多态性
公开(公告)号：WO2006035293A1
公开(公告)日：2006-04-06
申请号：PCT/IB2005/002860
申请日：2005-09-27
申请人： RANBAXY LABORATORIES LIMITED , PANDYA, Bhargav , ARYAN, Ram, Chander , KUMAR, Yatendra
发明人： PANDYA, Bhargav , ARYAN, Ram, Chander , KUMAR, Yatendra
IPC分类号： C07D281/16
CPC分类号： C07D281/16
摘要： The present invention relates to novel polymorphic forms of quetiapine hemifumarate, process for their preparation and pharmaceutical compositions thereof.
摘要翻译：本发明涉及喹硫平半富马酸盐的新型多晶型物，其制备方法及其药物组合物。

4. 发明申请

WO2006030300A2 PROCESSES FOR THE PREPARATION OF OLANZAPINE 审中-公开
标题翻译：制备氯氮平的过程
公开(公告)号：WO2006030300A2
公开(公告)日：2006-03-23
申请号：PCT/IB2005/002749
申请日：2005-09-16
申请人： RANBAXY LABORATORIES LIMITED , PANDYA, Bhargav, R. , ARYAN, Ram, Chander , KUMAR, Yatendra
发明人： PANDYA, Bhargav, R. , ARYAN, Ram, Chander , KUMAR, Yatendra
IPC分类号： C07D495/04 , A61K31/551 , A61P25/18
CPC分类号： C07D495/04
摘要： The invention relates to processes for the preparation of a crystalline polymorphic form of olanzapine. More particularly, it relates to the preparation of a crystalline polymorphic form of olanzapine designated as Form X and to pharmaceutical compositions that include the polymorphic Form X. The invention also relates to a process for the preparation of a methanol solvate of olanzapine and a process for using such solvate.
摘要翻译：本发明涉及制备奥氮平的结晶多晶型物的方法。更具体地说，它涉及制备称为晶型X的奥氮平的结晶多晶型物和制备包含多晶型物X的药物组合物。本发明还涉及制备奥氮平的甲醇溶剂化物的方法和用于制备奥氮平的方法使用这种溶剂化物。

5. 发明申请

WO2012044462A8 ECHO CONTROL OPTIMIZATION 审中-公开
标题翻译： ECHO控制优化
公开(公告)号：WO2012044462A8
公开(公告)日：2013-02-28
申请号：PCT/US2011051692
申请日：2011-09-15
申请人： CISCO TECH INC , RAMALINGAM THIYAGESAN , PANDYA BHARGAV G , SKRABUTENAS GARY A
发明人： RAMALINGAM THIYAGESAN , PANDYA BHARGAV G , SKRABUTENAS GARY A
IPC分类号： H04M9/08 , H04B3/23
CPC分类号： H04B3/23
摘要： In one implementation, a conference hosted on a conference bridge that includes an echo control device that classifies the echo return loss of a plurality of endpoints. The endpoints may include endpoints on internet protocol (IP) networks and public switched telephone networks (PSTN). The echo control of the endpoints is controlled independently. An echo classification module calculates the echo return loss value of the associated echo tail of the endpoint and chooses an appropriate echo control mode. If the echo return loss is above a high threshold, a pass through mode is activated. If the echo return loss is below a low threshold, a full echo cancellation mode is activated. If the echo return loss is between the low threshold and the high threshold, an echo suppression mode is activated.
摘要翻译：在一个实现中，在会议桥上托管的会议，其包括对多个端点的回波返回损失进行分类的回波控制设备。端点可以包括互联网协议（IP）网络和公共交换电话网络（PSTN）上的端点。端点的回波控制是独立控制的。回波分类模块计算端点的相关回波尾的回波回波损耗值，并选择适当的回波控制模式。如果回波回波损耗高于高阈值，则激活通过模式。如果回波回波损耗低于低阈值，则全反射消除模式被激活。如果回波回波损耗在低阈值和高阈值之间，则启用回波抑制模式。

6. 发明申请

WO2006040643A3 POLYMORPHIC FORMS OF EFAVIRENZ AND PROCESSES FOR THEIR PREPARATION 审中-公开
公开(公告)号：WO2006040643A3
公开(公告)日：2006-04-20
申请号：PCT/IB2005/003013
申请日：2005-10-10
申请人： RANBAXY LABORATORIES LIMITED , SHARMA, Ramnik , BHUSHAN, Kumar, Hari , ARYAN, Ram, Chander , SINGH, Nitu , PANDYA, Bhargav , KUMAR, Yatendra
发明人： SHARMA, Ramnik , BHUSHAN, Kumar, Hari , ARYAN, Ram, Chander , SINGH, Nitu , PANDYA, Bhargav , KUMAR, Yatendra
IPC分类号： C07D265/18 , A61K31/535 , A61P31/18
摘要： The present invention relates to novel polymorphic forms of efavirenz. The novel polymorphic forms are designated as Forms α, β, γ, γ1, γ2, ω,δ, N, O and P of efavirenz. The present invention further relates to amorphous form of efavirenz. The invention also relates to the processes for their preparation and use in pharmaceutical compositions useful in the treatmentof HIV-1 infection.

7. 发明申请

WO2013011459A1 PROCESS FOR THE PREPARATION OF FONDAPARINUX 审中-公开
标题翻译： FONDAPARINUX的制备方法
公开(公告)号：WO2013011459A1
公开(公告)日：2013-01-24
申请号：PCT/IB2012/053649
申请日：2012-07-17
申请人： RANBAXY LABORATORIES LIMITED , PANDYA, Bhargav , NAGARAJU, P.
发明人： PANDYA, Bhargav , NAGARAJU, P.
IPC分类号： C07H7/033
CPC分类号： C07H7/033
摘要： The present invention relates to process for preparation of O-(2,3-Di-O-benzyl- β -D-glucopyranuronicacid)-(1→4)-3-O-acetyl-1,6-anhydro-2-azido-2-deoxy- β -D-glucopyranose represented by Formula (II) comprising oxidation of O-(2,3-Di-O-benzyl- β -D-glucopyranosyl)-(1→4)-3-O-acetyl-1,6-anhydro-2-azido-2-deoxy- β -D-glucopyranose represented by Formula (I) with N-bromosuccinamide (NBS), bisacetoxy iodobenzene (iodobenzene diacetate) or mixture thereof, optionally in presence of 2,2,6,6-tetramethylpiperidine-1-oxyl (hereinafter referred as TEMPO). The process of the invention are useful for the production of fondaparinux sodium, a heparin and blood clotting factor Xa inhibitor.
摘要翻译：本发明涉及制备O-（2,3-二-O-苄基-β-D-吡喃葡萄糖醛酸） - （1→4）-3-O-乙酰基-1,6-脱水-2-叠氮基由式（II）表示的包含O-（2,3-二-O-苄基-β-D-吡喃葡萄糖基） - （1→4）-3-O-乙酰基的氧化的2-脱氧-β-D-吡喃葡萄糖由式（I）代表的具有N-溴代琥珀酰胺（NBS），双乙酰氧基碘苯（二乙酸碘苯）或其混合物的-1,6-脱水-2-叠氮基-2-脱氧-β-D-吡喃葡萄糖， 2,6,6-四甲基哌啶-1-氧基（以下称TEMPO）。本发明的方法可用于生产磺达肝素钠，肝素和凝血因子Xa抑制剂。

8. 发明申请

WO2006018807A8 CRYSTALLINE FORMS OF CEFDINIR 审中-公开
标题翻译： CEFDINIR的晶体形式
公开(公告)号：WO2006018807A8
公开(公告)日：2006-08-10
申请号：PCT/IB2005052691
申请日：2005-08-15
申请人： RANBAXY LAB LTD , MAHENDRU MANU , ARYAN RAM CHANDER , KUMAR SATISH , PANDYA BHARGAV , DUGGAL SANJAM , GADE SANJAY , KUMAR YATENDRA
发明人： MAHENDRU MANU , ARYAN RAM CHANDER , KUMAR SATISH , PANDYA BHARGAV , DUGGAL SANJAM , GADE SANJAY , KUMAR YATENDRA
IPC分类号： C07D501/00 , A61K31/546 , A61P31/04
CPC分类号： C07D501/00
摘要： The invention relates to processes for the preparation of crystalline polymorphic forms of cefdinir of formula I. More particularly, it relates to the preparation of crystalline polymorphic forms of cefdinir designated as Forms B and C. The invention also relates to pharmaceutical compositions that include the polymorphic forms B and C, and the use of the compositions for treating bacterial infections.
摘要翻译：本发明涉及用于制备式I的头孢地尼的结晶多晶形式的方法。更具体地说，本发明涉及被称为形式B和C的头孢地尼的结晶多晶形式的制备。本发明还涉及药物组合物，其包括多晶型物形式B和C，以及组合物用于治疗细菌感染的用途。

9. 发明申请

WO2006030300A3 PROCESSES FOR THE PREPARATION OF OLANZAPINE 审中-公开
标题翻译：制备奥兰波星的方法
公开(公告)号：WO2006030300A3
公开(公告)日：2006-06-01
申请号：PCT/IB2005002749
申请日：2005-09-16
申请人： RANBAXY LAB LTD , PANDYA BHARGAV R , ARYAN RAM CHANDER , KUMAR YATENDRA
发明人： PANDYA BHARGAV R , ARYAN RAM CHANDER , KUMAR YATENDRA
IPC分类号： C07D495/04 , A61K31/551 , A61P25/18
CPC分类号： C07D495/04
摘要： The invention relates to processes for the preparation of a crystalline polymorphic form of olanzapine. More particularly, it relates to the preparation of a crystalline polymorphic form of olanzapine designated as Form X and to pharmaceutical compositions that include the polymorphic Form X. The invention also relates to a process for the preparation of a methanol solvate of olanzapine and a process for using such solvate.
摘要翻译：本发明涉及制备奥氮平结晶多晶型物的方法。更具体地说，本发明涉及称为形式X的奥氮平结晶多晶型物的制备以及包含多晶型X的药物组合物。本发明还涉及制备奥氮平的甲醇溶剂合物的方法和使用这种溶剂合物。

10. 发明申请

WO2006040645A1 N-(3,5-DICHLOROPYRIDIN-4-YL)-2,4,5-ALKOXY AND 2,3,4-ALKOXY BENZAMIDE DERIVATIVES AS PDE-IV (PHOPHODIESTERASE TYPE-IV) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES SUCH AS ASTHMA 审中-公开
标题翻译：作为治疗炎症性疾病的PDE-IV（PHOPHODIESTERASE TY-IV）抑制剂的N-（3,5-二氯吡啶-4-基）-2,4,5-烷氧基和2,3,4-烷氧基苯甲酰胺衍生物哮喘
公开(公告)号：WO2006040645A1
公开(公告)日：2006-04-20
申请号：PCT/IB2005/003017
申请日：2005-10-11
申请人： RANBAXY LABORATORIES LIMITED , SHARMA, Ramnik , BHUSHAN, Kumar, Hari , PANDYA, Bhargav , ARYAN, Ram, Chander , KUMAR, Yatendra
发明人： SHARMA, Ramnik , BHUSHAN, Kumar, Hari , PANDYA, Bhargav , ARYAN, Ram, Chander , KUMAR, Yatendra
IPC分类号： C07D213/75 , C07C235/56 , A61P11/06
CPC分类号： C07D213/75 , C07D213/89
摘要： The present invention relates to benzamide derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV, having the structure of Formula (I), its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers of N-oxides wherein R1 is hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, aralkyl, heterocyclylalkyl, heteroarylalkyl or cycloalkylalkyl; R2 is aryl, heteroaryl, heterocyclyl of cycloalkyl; and R3 is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, aralkyl, heterocyclylalkyl, heteroarylalkyl or cycloalkylalkyl. Compounds disclosed herein can be useful in the treatment of inflammatory diseases, AIDS, asthma, arthritis, bronchitis, chronic obstructer pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn’ s disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis and ulcerative colitis.
摘要翻译：本发明涉及苯甲酰胺衍生物，其可用作IV型磷酸二酯酶（PDE）的选择性抑制剂，其具有式（I）的结构，其药学上可接受的盐，药学上可接受的溶剂合物，对映异构体，N-氧化物的非对映异构体，其中R1 烷基，烯基，炔基，芳基，环烷基，杂芳基，杂环基，芳烷基，杂环基烷基，杂芳基烷基或环烷基烷基; R2是芳基，杂芳基，环烷基的杂环基; R 3为烷基，烯基，炔基，芳基，环烷基，杂芳基，杂环基，芳烷基，杂环基烷基，杂芳基烷基或环烷基烷基。本文公开的化合物可用于治疗炎性疾病，AIDS，哮喘，关节炎，支气管炎，慢性阻塞性肺疾病（COPD），牛皮癣，过敏性鼻炎，休克，特应性皮炎，克罗恩病，成人呼吸窘迫综合征（ARDS ），嗜酸性肉芽肿，过敏性结膜炎，骨关节炎和溃疡性结肠炎。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式